Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Mesothelioma | Research

Predicting survival for patients with mesothelioma: development of the PLACE prognostic model

Authors: Yuan Zhang, Nan Li, Ran Li, Yumei Gu, Xiaofang Liu, Shu Zhang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Introduction

The overall survival of patients with mesothelioma is poor and heterogeneous. At present, the prediction model for Chinese patients needs to be improved. We sought to investigate predictors of survival in malignant pleural mesothelioma and develop prognostic prediction models.

Methods

This Two-center retrospective cohort study recruited patients with pathologically diagnosed mesothelioma at Beijing Chao-Yang Hospital and Beijing Tong-Ren Hospital. We developed a new prognostic prediction model based on COX multivariable analysis using data from patients who were recruited from June 1, 2010 to July 1, 2021 in Beijing Chao-Yang Hospital (n = 95, development cohort) and validated this model using data from patients recruited from July 18, 2014 to May 9, 2022 in Beijing Tong-Ren Hospital (n = 23, validation cohort). Receiver operating characteristic analysis was used to estimate model accuracy.

Results

The parameters in this new model included PLT > 289.5(10^9/L) (1 point), Lymphocyte > 1.785(10^9/L) (-1point), Age > 73 years old (1 point), Calcium > 2.145(mmol/L) (-1point), Eastern Cooperative Oncology Group performance status (ECOG PS) > 2 (2 points). When the sum of scores < 0, it is recognized as a low-risk group; when the score is 0 ~ 3, it is recognized as a high-risk group. The survival rate of patients in the high-risk group was significantly lower than that in the low-risk group (hazard ratio [HR], 3.878; 95% confidence interval [CI], 2.226–6.755; P < 0.001). The validation group had similar results (HR,3.574; 95%CI,1.064–12.001; P = 0.039). Furthermore, the areas under the curve 6 months after diagnosis in the two cohorts were 0.900 (95% CI: 0.839–0.962) and 0.761 (95% CI: 0.568–0.954) for development and validation cohorts, respectively.

Conclusion

We developed a simple, clinically relevant prognostic prediction model for PLACE by evaluating five variables routinely tested at the time of diagnosis. The predictive model can differentiate patients of Chinese ethnicity into different risk groups and further guide prognosis.
Literature
1.
go back to reference Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, Husain AN, Kadota K, Khoor A, Nicholson AG, et al. The 2021 WHO classification of tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608–22.PubMedCrossRef Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, Husain AN, Kadota K, Khoor A, Nicholson AG, et al. The 2021 WHO classification of tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608–22.PubMedCrossRef
2.
go back to reference Tsao A, Wistuba I, Roth J, Kindler H. Malignant pleural mesothelioma. J Clin oncology: official J Am Soc Clin Oncol. 2009;27(12):2081–90.CrossRef Tsao A, Wistuba I, Roth J, Kindler H. Malignant pleural mesothelioma. J Clin oncology: official J Am Soc Clin Oncol. 2009;27(12):2081–90.CrossRef
3.
go back to reference Patel A, Bogner P, Klippenstein D, Ramnath N. Malignant pleural mesothelioma after household exposure to asbestos. J Clin oncology: official J Am Soc Clin Oncol. 2008;26(33):5480–3.CrossRef Patel A, Bogner P, Klippenstein D, Ramnath N. Malignant pleural mesothelioma after household exposure to asbestos. J Clin oncology: official J Am Soc Clin Oncol. 2008;26(33):5480–3.CrossRef
4.
go back to reference Menis J, Pasello G, Remon J. Immunotherapy in malignant pleural mesothelioma: a review of literature data. Translational lung cancer research. 2021;10(6):2988–3000.PubMedPubMedCentralCrossRef Menis J, Pasello G, Remon J. Immunotherapy in malignant pleural mesothelioma: a review of literature data. Translational lung cancer research. 2021;10(6):2988–3000.PubMedPubMedCentralCrossRef
5.
go back to reference Yap T, Aerts J, Popat S, Fennell D. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475–88.PubMedCrossRef Yap T, Aerts J, Popat S, Fennell D. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475–88.PubMedCrossRef
6.
go back to reference Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10(1):1333.PubMedPubMedCentralCrossRef Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10(1):1333.PubMedPubMedCentralCrossRef
7.
go back to reference Lee Y. Surgical resection of mesothelioma: an evidence-free practice. Lancet (London England). 2014;384(9948):1080–1.PubMedCrossRef Lee Y. Surgical resection of mesothelioma: an evidence-free practice. Lancet (London England). 2014;384(9948):1080–1.PubMedCrossRef
8.
go back to reference Treasure T, Lang-Lazdunski L, Waller D, Bliss J, Tan C, Entwisle J, Snee M, O’Brien M, Thomas G, Senan S, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72.PubMedPubMedCentralCrossRef Treasure T, Lang-Lazdunski L, Waller D, Bliss J, Tan C, Entwisle J, Snee M, O’Brien M, Thomas G, Senan S, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72.PubMedPubMedCentralCrossRef
9.
go back to reference Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin oncology: official J Am Soc Clin Oncol. 2003;21(14):2636–44.CrossRef Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin oncology: official J Am Soc Clin Oncol. 2003;21(14):2636–44.CrossRef
10.
go back to reference Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet (London England). 2016;387(10026):1405–14.PubMedCrossRef Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet (London England). 2016;387(10026):1405–14.PubMedCrossRef
11.
go back to reference Gounant V, Brosseau S, Zalcman G. Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment. Therapeutic Adv Med Oncol. 2021;13:17588359211061956. Gounant V, Brosseau S, Zalcman G. Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment. Therapeutic Adv Med Oncol. 2021;13:17588359211061956.
12.
go back to reference Dozier J, Zheng H, Adusumilli P. Immunotherapy for malignant pleural mesothelioma: current status and future directions. Translational lung cancer research. 2017;6(3):315–24.PubMedPubMedCentralCrossRef Dozier J, Zheng H, Adusumilli P. Immunotherapy for malignant pleural mesothelioma: current status and future directions. Translational lung cancer research. 2017;6(3):315–24.PubMedPubMedCentralCrossRef
13.
go back to reference Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A, Mansfield A, Popat S, Jahan T, Antonia S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet (London England). 2021;397(10272):375–86.PubMedCrossRef Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A, Mansfield A, Popat S, Jahan T, Antonia S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet (London England). 2021;397(10272):375–86.PubMedCrossRef
14.
go back to reference Clive A, Bhatnagar R, Psallidas I, Maskell N. Individualised management of malignant pleural effusion. The Lancet Respiratory medicine. 2015;3(7):505–6.PubMedCrossRef Clive A, Bhatnagar R, Psallidas I, Maskell N. Individualised management of malignant pleural effusion. The Lancet Respiratory medicine. 2015;3(7):505–6.PubMedCrossRef
15.
go back to reference Tanrikulu A, Abakay A, Komek H, Abakay O. Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma. Environ Health Prev Med. 2016;21(5):304–11.PubMedPubMedCentralCrossRef Tanrikulu A, Abakay A, Komek H, Abakay O. Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma. Environ Health Prev Med. 2016;21(5):304–11.PubMedPubMedCentralCrossRef
16.
go back to reference Tural Onur S, Sokucu S, Dalar L, Iliaz S, Kara K, Buyukkale S, Altin S. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? Ther Clin Risk Manag. 2016;12:651–6.PubMedPubMedCentralCrossRef Tural Onur S, Sokucu S, Dalar L, Iliaz S, Kara K, Buyukkale S, Altin S. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? Ther Clin Risk Manag. 2016;12:651–6.PubMedPubMedCentralCrossRef
17.
go back to reference Pinato D, Mauri F, Ramakrishnan R, Wahab L, Lloyd T, Sharma R. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac oncology: official publication Int Association Study Lung Cancer. 2012;7(3):587–94.CrossRef Pinato D, Mauri F, Ramakrishnan R, Wahab L, Lloyd T, Sharma R. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac oncology: official publication Int Association Study Lung Cancer. 2012;7(3):587–94.CrossRef
18.
go back to reference Vigneri P, Martorana F, Manzella L, Stella S. Biomarkers and prognostic factors for malignant pleural mesothelioma. Future Oncol (London England). 2015;11:29–33.CrossRef Vigneri P, Martorana F, Manzella L, Stella S. Biomarkers and prognostic factors for malignant pleural mesothelioma. Future Oncol (London England). 2015;11:29–33.CrossRef
19.
go back to reference Pavic M, Bogowicz M, Kraft J, Vuong D, Mayinger M, Kroeze S, Friess M, Frauenfelder T, Andratschke N, Huellner M, et al. FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients. EJNMMI Res. 2020;10(1):81.PubMedPubMedCentralCrossRef Pavic M, Bogowicz M, Kraft J, Vuong D, Mayinger M, Kroeze S, Friess M, Frauenfelder T, Andratschke N, Huellner M, et al. FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients. EJNMMI Res. 2020;10(1):81.PubMedPubMedCentralCrossRef
20.
go back to reference Leuzzi G, Rea F, Spaggiari L, Marulli G, Sperduti I, Alessandrini G, Casiraghi M, Bovolato P, Pariscenti G, Alloisio M, et al. Prognostic score of long-term survival after surgery for malignant pleural mesothelioma: a Multicenter Analysis. Ann Thorac Surg. 2015;100(3):890–7.PubMedCrossRef Leuzzi G, Rea F, Spaggiari L, Marulli G, Sperduti I, Alessandrini G, Casiraghi M, Bovolato P, Pariscenti G, Alloisio M, et al. Prognostic score of long-term survival after surgery for malignant pleural mesothelioma: a Multicenter Analysis. Ann Thorac Surg. 2015;100(3):890–7.PubMedCrossRef
21.
go back to reference Ma M, Yu N, Wu B. High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma. Cancer Manage Res. 2019;11:3973–9.CrossRef Ma M, Yu N, Wu B. High systemic immune-inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma. Cancer Manage Res. 2019;11:3973–9.CrossRef
22.
go back to reference Ghanim B, Hoda M, Winter M, Klikovits T, Alimohammadi A, Hegedus B, Dome B, Grusch M, Arns M, Schenk P, et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg. 2012;256(2):357–62.PubMedCrossRef Ghanim B, Hoda M, Winter M, Klikovits T, Alimohammadi A, Hegedus B, Dome B, Grusch M, Arns M, Schenk P, et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg. 2012;256(2):357–62.PubMedCrossRef
23.
go back to reference Linton A, Pavlakis N, O’Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014;111(9):1860–9.PubMedPubMedCentralCrossRef Linton A, Pavlakis N, O’Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014;111(9):1860–9.PubMedPubMedCentralCrossRef
24.
go back to reference Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen-Kim T, Seifert B, Hoda M, Klepetko W, Stahel R, et al. A new Prognostic score supporting treatment allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: a review of 12 years’ experience. J Thorac oncology: official publication Int Association Study Lung Cancer. 2015;10(11):1634–41.CrossRef Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen-Kim T, Seifert B, Hoda M, Klepetko W, Stahel R, et al. A new Prognostic score supporting treatment allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: a review of 12 years’ experience. J Thorac oncology: official publication Int Association Study Lung Cancer. 2015;10(11):1634–41.CrossRef
25.
go back to reference Brims F, Meniawy T, Duffus I, de Fonseka D, Segal A, Creaney J, Maskell N, Lake R, de Klerk N, Nowak A. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma using decision Tree Analysis. J Thorac oncology: official publication Int Association Study Lung Cancer. 2016;11(4):573–82.CrossRef Brims F, Meniawy T, Duffus I, de Fonseka D, Segal A, Creaney J, Maskell N, Lake R, de Klerk N, Nowak A. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma using decision Tree Analysis. J Thorac oncology: official publication Int Association Study Lung Cancer. 2016;11(4):573–82.CrossRef
26.
go back to reference Yeap B, De Rienzo A, Gill R, Oster M, Dao M, Dao N, Levy R, Vermilya K, Gustafson C, Ovsak G, et al. Mesothelioma Risk score: a New Prognostic pretreatment, clinical-molecular Algorithm for Malignant Pleural Mesothelioma. J Thorac oncology: official publication Int Association Study Lung Cancer. 2021;16(11):1925–35.CrossRef Yeap B, De Rienzo A, Gill R, Oster M, Dao M, Dao N, Levy R, Vermilya K, Gustafson C, Ovsak G, et al. Mesothelioma Risk score: a New Prognostic pretreatment, clinical-molecular Algorithm for Malignant Pleural Mesothelioma. J Thorac oncology: official publication Int Association Study Lung Cancer. 2021;16(11):1925–35.CrossRef
27.
go back to reference Clive A, Kahan B, Hooper C, Bhatnagar R, Morley A, Zahan-Evans N, Bintcliffe O, Boshuizen R, Fysh E, Tobin C, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–104.PubMedCrossRef Clive A, Kahan B, Hooper C, Bhatnagar R, Morley A, Zahan-Evans N, Bintcliffe O, Boshuizen R, Fysh E, Tobin C, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–104.PubMedCrossRef
28.
go back to reference Zhang S, Zhang Y, Feng W, Shi Z, Shi H, Zhang Y. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion. Thorac Cancer. 2021;12(24):3304–9.PubMedPubMedCentralCrossRef Zhang S, Zhang Y, Feng W, Shi Z, Shi H, Zhang Y. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion. Thorac Cancer. 2021;12(24):3304–9.PubMedPubMedCentralCrossRef
29.
go back to reference Zhai Y, Hui Z, Chen W, Ying J, Li J, Gao S. The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–2030. Transl Lung Cancer Res. 2022;11(12):2403–11.PubMedPubMedCentralCrossRef Zhai Y, Hui Z, Chen W, Ying J, Li J, Gao S. The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–2030. Transl Lung Cancer Res. 2022;11(12):2403–11.PubMedPubMedCentralCrossRef
30.
go back to reference [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma. (2021 Edition)]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2021, 43(4):383–394. [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma. (2021 Edition)]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2021, 43(4):383–394.
31.
go back to reference Yeap BY, De Rienzo A, Gill RR, Oster ME, Dao MN, Dao NT, Levy RD, Vermilya K, Gustafson CE, Ovsak G, et al. Mesothelioma Risk score: a New Prognostic pretreatment, clinical-molecular Algorithm for Malignant Pleural Mesothelioma. J Thorac Oncol. 2021;16(11):1925–35.PubMedPubMedCentralCrossRef Yeap BY, De Rienzo A, Gill RR, Oster ME, Dao MN, Dao NT, Levy RD, Vermilya K, Gustafson CE, Ovsak G, et al. Mesothelioma Risk score: a New Prognostic pretreatment, clinical-molecular Algorithm for Malignant Pleural Mesothelioma. J Thorac Oncol. 2021;16(11):1925–35.PubMedPubMedCentralCrossRef
32.
go back to reference Messina G, Bove M, Natale G, Di Filippo V, Opromolla G, Rainone A, Leonardi B, Martone M, Fiorelli A, Vicidomini G et al. Diagnosis of malignant pleural disease: Ultrasound as “a detective probe”. Thorac Cancer 2022. Messina G, Bove M, Natale G, Di Filippo V, Opromolla G, Rainone A, Leonardi B, Martone M, Fiorelli A, Vicidomini G et al. Diagnosis of malignant pleural disease: Ultrasound as “a detective probe”. Thorac Cancer 2022.
33.
go back to reference Ossowski S, Hung YY, Banks K, Hsu D, Herrinton L, Ashiku S, Patel A, Suga JM, Velotta JB. Improving outcomes in malignant pleural mesothelioma in an integrated health care system. J Thorac Dis. 2022;14(9):3352–63.PubMedPubMedCentralCrossRef Ossowski S, Hung YY, Banks K, Hsu D, Herrinton L, Ashiku S, Patel A, Suga JM, Velotta JB. Improving outcomes in malignant pleural mesothelioma in an integrated health care system. J Thorac Dis. 2022;14(9):3352–63.PubMedPubMedCentralCrossRef
34.
go back to reference Zhang Y, Tang J, Zhou X, Chen W, Zhang S, Li Y, Zhou D, He L, Tang Q. Diagnostic ability and its influenced factors of ultrasound-guided percutaneous pleural needle biopsy diagnosis for malignant pleural mesothelioma. Front Surg. 2022;9:1022505.PubMedPubMedCentralCrossRef Zhang Y, Tang J, Zhou X, Chen W, Zhang S, Li Y, Zhou D, He L, Tang Q. Diagnostic ability and its influenced factors of ultrasound-guided percutaneous pleural needle biopsy diagnosis for malignant pleural mesothelioma. Front Surg. 2022;9:1022505.PubMedPubMedCentralCrossRef
35.
go back to reference Cimen F, Agackiran Y, Duzgun S, Aloglu M, Senturk A, Atikcan S. Factors affecting the life expectancy in malignant pleural mesothelioma: our 10 years of studies and experience. Med (Baltim). 2022;101(39):e30711.CrossRef Cimen F, Agackiran Y, Duzgun S, Aloglu M, Senturk A, Atikcan S. Factors affecting the life expectancy in malignant pleural mesothelioma: our 10 years of studies and experience. Med (Baltim). 2022;101(39):e30711.CrossRef
36.
go back to reference Chouaid C, Assie JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC. Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. Cancer Med. 2018;7(4):1102–9.PubMedPubMedCentralCrossRef Chouaid C, Assie JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC. Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. Cancer Med. 2018;7(4):1102–9.PubMedPubMedCentralCrossRef
37.
go back to reference Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009;69(11):4598–604.PubMedCrossRef Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009;69(11):4598–604.PubMedCrossRef
38.
go back to reference Taioli E, Wolf AS, Camacho-Rivera M, Flores RM. Women with malignant pleural mesothelioma have a threefold better survival rate than men. Ann Thorac Surg. 2014;98(3):1020–4.PubMedCrossRef Taioli E, Wolf AS, Camacho-Rivera M, Flores RM. Women with malignant pleural mesothelioma have a threefold better survival rate than men. Ann Thorac Surg. 2014;98(3):1020–4.PubMedCrossRef
39.
go back to reference Brims FJ, Meniawy TM, Duffus I, de Fonseka D, Segal A, Creaney J, Maskell N, Lake RA, de Klerk N, Nowak AK. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma using decision Tree Analysis. J Thorac Oncol. 2016;11(4):573–82.PubMedCrossRef Brims FJ, Meniawy TM, Duffus I, de Fonseka D, Segal A, Creaney J, Maskell N, Lake RA, de Klerk N, Nowak AK. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma using decision Tree Analysis. J Thorac Oncol. 2016;11(4):573–82.PubMedCrossRef
40.
go back to reference Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, Boshuizen RC, Fysh ET, Tobin CL, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–104.PubMedCrossRef Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, Boshuizen RC, Fysh ET, Tobin CL, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–104.PubMedCrossRef
41.
go back to reference Taioli E, Wolf AS, Moline JM, Camacho-Rivera M, Flores RM. Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma. Dis Markers 2015, 2015:282145. Taioli E, Wolf AS, Moline JM, Camacho-Rivera M, Flores RM. Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma. Dis Markers 2015, 2015:282145.
42.
go back to reference Saddoughi SA, Abdelsattar ZM, Blackmon SH. National Trends in the epidemiology of malignant pleural mesothelioma: a National Cancer Data Base Study. Ann Thorac Surg. 2018;105(2):432–7.PubMedCrossRef Saddoughi SA, Abdelsattar ZM, Blackmon SH. National Trends in the epidemiology of malignant pleural mesothelioma: a National Cancer Data Base Study. Ann Thorac Surg. 2018;105(2):432–7.PubMedCrossRef
43.
go back to reference Flores RM, Riedel E, Donington JS, Alago W, Ihekweazu U, Krug L, Rosenzweig K, Adusumilli PS, Carbone M, Pass HI. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and end results [SEER]) population. J Thorac Oncol. 2010;5(10):1649–54.PubMedCrossRef Flores RM, Riedel E, Donington JS, Alago W, Ihekweazu U, Krug L, Rosenzweig K, Adusumilli PS, Carbone M, Pass HI. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and end results [SEER]) population. J Thorac Oncol. 2010;5(10):1649–54.PubMedCrossRef
44.
go back to reference Remon J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo J, López R, Cilleruelo A, García-Campelo R, Martín P, et al. Malignant pleural mesothelioma: treatment patterns and outcomes from the spanish Lung Cancer Group. Lung cancer (Amsterdam Netherlands). 2020;147:83–90.PubMedCrossRef Remon J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo J, López R, Cilleruelo A, García-Campelo R, Martín P, et al. Malignant pleural mesothelioma: treatment patterns and outcomes from the spanish Lung Cancer Group. Lung cancer (Amsterdam Netherlands). 2020;147:83–90.PubMedCrossRef
45.
go back to reference Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020, 55(6). Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 2020, 55(6).
46.
go back to reference McCambridge A, Napolitano A, Mansfield A, Fennell D, Sekido Y, Nowak A, Reungwetwattana T, Mao W, Pass H, Carbone M, et al. Progress in the management of malignant pleural mesothelioma in 2017. J Thorac oncology: official publication Int Association Study Lung Cancer. 2018;13(5):606–23.CrossRef McCambridge A, Napolitano A, Mansfield A, Fennell D, Sekido Y, Nowak A, Reungwetwattana T, Mao W, Pass H, Carbone M, et al. Progress in the management of malignant pleural mesothelioma in 2017. J Thorac oncology: official publication Int Association Study Lung Cancer. 2018;13(5):606–23.CrossRef
47.
go back to reference Chen S, Yu W, Shao S, Xiao J, Bai H, Pu Y, Li M. Establishment of predictive nomogram and web-based survival risk calculator for malignant pleural mesothelioma: a SEER database analysis. Front Oncol. 2022;12:1027149.PubMedPubMedCentralCrossRef Chen S, Yu W, Shao S, Xiao J, Bai H, Pu Y, Li M. Establishment of predictive nomogram and web-based survival risk calculator for malignant pleural mesothelioma: a SEER database analysis. Front Oncol. 2022;12:1027149.PubMedPubMedCentralCrossRef
48.
go back to reference Jiang Y, Zhang C, Chen Y, Zhao S, He Y, He J. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma. Cancer Med 2022. Jiang Y, Zhang C, Chen Y, Zhao S, He Y, He J. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma. Cancer Med 2022.
49.
go back to reference Asciak R, Kanellakis N, Bibby A, Kidd A, Gerry S, Mercer R, Maskell N, Blyth K, Fsadni P, Montefort S et al. The association between pleural fluid exposure and survival in pleural mesothelioma. Chest 2021. Asciak R, Kanellakis N, Bibby A, Kidd A, Gerry S, Mercer R, Maskell N, Blyth K, Fsadni P, Montefort S et al. The association between pleural fluid exposure and survival in pleural mesothelioma. Chest 2021.
50.
go back to reference Ringgaard Petersen T, Panou V, Meristoudis C, Weinreich U, Røe O. Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting. Acta Oncol (Stockholm Sweden). 2021;60(4):521–7.CrossRef Ringgaard Petersen T, Panou V, Meristoudis C, Weinreich U, Røe O. Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting. Acta Oncol (Stockholm Sweden). 2021;60(4):521–7.CrossRef
51.
go back to reference Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, Klepstad P. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64.PubMedCrossRef Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, Klepstad P. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64.PubMedCrossRef
52.
go back to reference Rocha BM, Ross DD, Paiva CE, McGovern J, Paiva BS, Preto DD, Donald CM, Maia YC, Laird BJ. Inflammation and performance status: the cornerstones of prognosis in advanced cancer. J Pain Symptom Manage 2022. Rocha BM, Ross DD, Paiva CE, McGovern J, Paiva BS, Preto DD, Donald CM, Maia YC, Laird BJ. Inflammation and performance status: the cornerstones of prognosis in advanced cancer. J Pain Symptom Manage 2022.
53.
go back to reference Shiratori F, Suzuki T, Yajima S, Oshima Y, Nanami T, Funahashi K, Shimada H. Preoperative low serum calcium levels predict poor prognosis for patients with esophageal Cancer. Ann Thorac Cardiovasc Surg. 2022;28(2):96–102.PubMedCrossRef Shiratori F, Suzuki T, Yajima S, Oshima Y, Nanami T, Funahashi K, Shimada H. Preoperative low serum calcium levels predict poor prognosis for patients with esophageal Cancer. Ann Thorac Cardiovasc Surg. 2022;28(2):96–102.PubMedCrossRef
54.
go back to reference Xu J, Chen X, Wang X, Zhu C, Hu Y, Yang X, Xu C, Shen X. Preoperative hyponatremia and Hypocalcemia Predict Poor Prognosis in Elderly Gastric Cancer Patients. Cancer Manag Res. 2019;11:8765–80.PubMedPubMedCentralCrossRef Xu J, Chen X, Wang X, Zhu C, Hu Y, Yang X, Xu C, Shen X. Preoperative hyponatremia and Hypocalcemia Predict Poor Prognosis in Elderly Gastric Cancer Patients. Cancer Manag Res. 2019;11:8765–80.PubMedPubMedCentralCrossRef
55.
go back to reference Huang SY, Chen Y, Tan XR, Gong S, Yang XJ, He QM, He SW, Liu N, Li YQ. Serum calcium levels before Antitumour Therapy Predict Clinical Outcomes in patients with nasopharyngeal carcinoma. Onco Targets Ther. 2020;13:13111–9.PubMedPubMedCentralCrossRef Huang SY, Chen Y, Tan XR, Gong S, Yang XJ, He QM, He SW, Liu N, Li YQ. Serum calcium levels before Antitumour Therapy Predict Clinical Outcomes in patients with nasopharyngeal carcinoma. Onco Targets Ther. 2020;13:13111–9.PubMedPubMedCentralCrossRef
56.
go back to reference Gastanaga VM, Schwartzberg LS, Jain RK, Pirolli M, Quach D, Quigley JM, Mu G, Scott Stryker W, Liede A. Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med. 2016;5(8):2091–100.PubMedPubMedCentralCrossRef Gastanaga VM, Schwartzberg LS, Jain RK, Pirolli M, Quach D, Quigley JM, Mu G, Scott Stryker W, Liede A. Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med. 2016;5(8):2091–100.PubMedPubMedCentralCrossRef
57.
go back to reference Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71(4):1309–12.PubMedCrossRef Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71(4):1309–12.PubMedCrossRef
58.
go back to reference Ajero PM, Belsky JL, Prawius HD, Rella V. Chemotherapy-induced hypocalcemia. Endocr Pract. 2010;16(2):284–90.PubMedCrossRef Ajero PM, Belsky JL, Prawius HD, Rella V. Chemotherapy-induced hypocalcemia. Endocr Pract. 2010;16(2):284–90.PubMedCrossRef
59.
go back to reference Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors. 2014;6(2):5389.PubMedPubMedCentralCrossRef Mirrakhimov AE, Ali AM, Khan M, Barbaryan A. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors. 2014;6(2):5389.PubMedPubMedCentralCrossRef
60.
go back to reference Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017;7(1):3–17.PubMedCrossRef Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017;7(1):3–17.PubMedCrossRef
61.
go back to reference Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. Nat Rev Cancer. 2017;17(6):367–80.PubMedCrossRef Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. Nat Rev Cancer. 2017;17(6):367–80.PubMedCrossRef
62.
go back to reference Ranzato E, Martinotti S, Magnelli V, Murer B, Biffo S, Mutti L, Burlando B. Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2 + channel opening. J Cell Mol Med. 2012;16(11):2667–78.PubMedPubMedCentralCrossRef Ranzato E, Martinotti S, Magnelli V, Murer B, Biffo S, Mutti L, Burlando B. Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2 + channel opening. J Cell Mol Med. 2012;16(11):2667–78.PubMedPubMedCentralCrossRef
63.
go back to reference Cheng Y, Wright C, Kirschner M, Williams M, Sarun K, Sytnyk V, Leshchynska I, Edelman J, Vallely M, McCaughan B, et al. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by mir-17-5p and modulates cell migration in malignant pleural mesothelioma. Mol Cancer. 2016;15(1):44.PubMedPubMedCentralCrossRef Cheng Y, Wright C, Kirschner M, Williams M, Sarun K, Sytnyk V, Leshchynska I, Edelman J, Vallely M, McCaughan B, et al. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by mir-17-5p and modulates cell migration in malignant pleural mesothelioma. Mol Cancer. 2016;15(1):44.PubMedPubMedCentralCrossRef
64.
go back to reference Bille A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2016;11(2):249–55.PubMedCrossRef Bille A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2016;11(2):249–55.PubMedCrossRef
65.
go back to reference Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145–52.PubMedCrossRef Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145–52.PubMedCrossRef
66.
go back to reference Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723–31.PubMedCrossRef Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723–31.PubMedCrossRef
67.
go back to reference Kircheva DY, Husain AN, Watson S, Kindler HL, Durkin A, Vigneswaran WT. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016;49(6):1642–7.PubMedCrossRef Kircheva DY, Husain AN, Watson S, Kindler HL, Durkin A, Vigneswaran WT. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016;49(6):1642–7.PubMedCrossRef
68.
go back to reference Tagawa T, Anraku M, Morodomi Y, Takenaka T, Okamoto T, Takenoyama M, Ichinose Y, Maehara Y, Cho BC, Feld R, et al. Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. J Thorac Dis. 2015;7(11):1898–906.PubMedPubMedCentral Tagawa T, Anraku M, Morodomi Y, Takenaka T, Okamoto T, Takenoyama M, Ichinose Y, Maehara Y, Cho BC, Feld R, et al. Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. J Thorac Dis. 2015;7(11):1898–906.PubMedPubMedCentral
69.
go back to reference Alexandrakis MG, Passam FH, Perisinakis K, Ganotakis E, Margantinis G, Kyriakou DS, Bouros D. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med. 2002;96(8):553–8.PubMedCrossRef Alexandrakis MG, Passam FH, Perisinakis K, Ganotakis E, Margantinis G, Kyriakou DS, Bouros D. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med. 2002;96(8):553–8.PubMedCrossRef
70.
go back to reference Yin W, Zheng G, Su S, Liang Y. The value of COX-2, NF-κB, and blood routine indexes in the prognosis of malignant peritoneal mesothelioma. Oncol Res Treat. 2019;42(6):334–41.PubMedCrossRef Yin W, Zheng G, Su S, Liang Y. The value of COX-2, NF-κB, and blood routine indexes in the prognosis of malignant peritoneal mesothelioma. Oncol Res Treat. 2019;42(6):334–41.PubMedCrossRef
71.
go back to reference Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, D’Amato RJ, Klement GL, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15(2):265–73.PubMedCrossRef Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, D’Amato RJ, Klement GL, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15(2):265–73.PubMedCrossRef
72.
go back to reference Roberts H, Patsios D, Paul N, DePerrot M, Teel W, Bayanati H, Shepherd F, Johnston M. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac oncology: official publication Int Association Study Lung Cancer. 2009;4(5):620–8.CrossRef Roberts H, Patsios D, Paul N, DePerrot M, Teel W, Bayanati H, Shepherd F, Johnston M. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac oncology: official publication Int Association Study Lung Cancer. 2009;4(5):620–8.CrossRef
73.
go back to reference Cersosimo F, Barbarino M, Lonardi S, Vermi W, Giordano A, Bellan C, Giurisato E. Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms. Cancers 2021, 13(22). Cersosimo F, Barbarino M, Lonardi S, Vermi W, Giordano A, Bellan C, Giurisato E. Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms. Cancers 2021, 13(22).
74.
go back to reference Billé A, Krug L, Woo K, Rusch V, Zauderer M. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac oncology: official publication Int Association Study Lung Cancer. 2016;11(2):249–55.CrossRef Billé A, Krug L, Woo K, Rusch V, Zauderer M. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac oncology: official publication Int Association Study Lung Cancer. 2016;11(2):249–55.CrossRef
75.
go back to reference Marcq E, Siozopoulou V, De Waele J, van Audenaerde J, Zwaenepoel K, Santermans E, Hens N, Pauwels P, van Meerbeeck J, Smits E. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology. 2017;6(1):e1261241.PubMedCrossRef Marcq E, Siozopoulou V, De Waele J, van Audenaerde J, Zwaenepoel K, Santermans E, Hens N, Pauwels P, van Meerbeeck J, Smits E. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology. 2017;6(1):e1261241.PubMedCrossRef
76.
go back to reference Guazzelli A, Hussain M, Krstic-Demonacos M, Mutti L. Tremelimumab for the treatment of malignant mesothelioma. Expert Opin Biol Ther. 2015;15(12):1819–29.PubMedCrossRef Guazzelli A, Hussain M, Krstic-Demonacos M, Mutti L. Tremelimumab for the treatment of malignant mesothelioma. Expert Opin Biol Ther. 2015;15(12):1819–29.PubMedCrossRef
Metadata
Title
Predicting survival for patients with mesothelioma: development of the PLACE prognostic model
Authors
Yuan Zhang
Nan Li
Ran Li
Yumei Gu
Xiaofang Liu
Shu Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11180-y

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine